Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (61-70 of 164) with videos related to

Pageof 17
Sort By:
Blood Advances|August 2, 2021
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOPSophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, et al.
British Journal of Haematology|April 23, 2014
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemiaEdouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, et al.
British Journal of Haematology|August 20, 2008
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemiaBruno Cazin, Marine Divine, Stéphane Leprêtre, et al.
Blood|June 28, 2019
Prevalence of <i>BTK</i> and <i>PLCG2</i> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
British Journal of Haematology|August 18, 2018
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF studyEmmanuel Gyan, Anne Sonet, Pauline Brice, et al.
British Journal of Haematology|November 27, 2013
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosisClémentine Sarkozy, Lucile Baseggio, Pierre Feugier, et al.
Research Square|April 17, 2023
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantationSimona Pagliuca, Carmelo Gurnari, Colin Hercus, et al.
Nature Communications|May 31, 2023
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantationSimona Pagliuca, Carmelo Gurnari, Colin Hercus, et al.
Blood Advances|June 23, 2022
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trialVincent Camus, Aurélien Belot, Lucie Oberic, et al.
Pageof 17

Showing results (61-70 of 164) with videos related to

Sort By:
Pageof 17
Blood Advances|August 2, 2021
Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOPSophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, et al.
British Journal of Haematology|April 23, 2014
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemiaEdouard Cornet, Cécile Tomowiak, Aline Tanguy-Schmidt, et al.
British Journal of Haematology|August 20, 2008
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemiaBruno Cazin, Marine Divine, Stéphane Leprêtre, et al.
Blood|June 28, 2019
Prevalence of <i>BTK</i> and <i>PLCG2</i> mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Blood|February 17, 2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trialStephane Lepretre, Therese Aurran, Beatrice Mahé, et al.
British Journal of Haematology|August 18, 2018
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF studyEmmanuel Gyan, Anne Sonet, Pauline Brice, et al.
British Journal of Haematology|November 27, 2013
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosisClémentine Sarkozy, Lucile Baseggio, Pierre Feugier, et al.
Research Square|April 17, 2023
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantationSimona Pagliuca, Carmelo Gurnari, Colin Hercus, et al.
Nature Communications|May 31, 2023
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantationSimona Pagliuca, Carmelo Gurnari, Colin Hercus, et al.
Blood Advances|June 23, 2022
Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trialVincent Camus, Aurélien Belot, Lucie Oberic, et al.
Pageof 17